Abstract
This cross-sectional study examines how information on overall survival benefits of novel cancer drug indications is communicated in labeling.
MeSH terms
-
Access to Information
-
Antineoplastic Agents / pharmacology*
-
Data Display*
-
Drug Approval / methods
-
Drug Labeling* / methods
-
Drug Labeling* / standards
-
Humans
-
Neoplasms* / drug therapy
-
Neoplasms* / mortality
-
Research Design / standards*
-
Survival Analysis
-
United States
-
United States Food and Drug Administration